Skip to content
Screener

Moderna MRNA Common Stock Shares Issued

Common Stock Shares Issued at other companies

ALN
Alnylam PharmaceuticalsALNY
133.7M+2.1%
Roivant Sciences logo
Roivant SciencesROIV
722.7M+5.9%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
144.3M+11.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
113.2M+38.7%
Gilead Sciences logo
Gilead SciencesGILD
1.2B-0.1%

Other financials

Income statement

See full
Revenue$145.0M+2.1%
Gross profit$52.0M+126%
Operating income-$815.0M+10.1%
Net income-$782.0M+5.2%
EPS (diluted)-$1.97+7.5%

Balance sheet

See full
Cash & equivalents$1.7B+34.5%
Total debt$1.2B+60.8%
Total equity$6.8B-28.1%
Total assets$11.0B-8.7%

Cash flow

See full
Operating cash flow-$526.0M+42.8%
CapEx$37.0M+1,133%
Free cash flow-$563.0M+38.9%

Valuation

See full
Market cap$23.88B+141%
Enterprise value$23.39B+149%
P/S10.7×+7.5×

Profitability

See full
Gross margin23.4%-29.1pp
Operating margin-149%+99.9pp
Net margin-141.4%+141pp
FCF margin-132.4%

Returns & leverage

See full
Return on equity-39%+28.0pp
Debt / equity0.2×+0.1×
Current ratio2.3×-1.6×

Where this comes from

Reported directly by Moderna in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Moderna’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001682852-26-000060
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, par value $0.0001; 162 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding at March 31, 2026 and December 31, 2025
Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2026 and December 31, 2025; 397 and 394 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Additional paid-in capital1,5031,382
Accumulated other comprehensive income2545
Retained earnings5,8807,223
Total stockholders’ equity7,4088,650

Item 1. Financial Statements (Unaudited)

FAQ

What is Moderna's common stock shares issued?
Moderna (MRNA) reported common stock shares issued of 397M in Q1 2026.
How has Moderna's common stock shares issued changed year-over-year?
Moderna's common stock shares issued increased by 2.6% year-over-year, from 387M to 397M.
What is the long-term trend for Moderna's common stock shares issued?
Over 5 years (2020 to 2025), Moderna's common stock shares issued has grown at a -0.3% compound annual growth rate (CAGR), from 399M to 394M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Moderna's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude